A New Way To Combat Lung Cancer

may have another weapon in their arsenal fordeveloping lung cancer-along with secondhand
fighting lung cancer. The single largest cancer killerexposure to cigarette smoke. Other risk factors
among men and women in the U.S., the disease isinclude exposure to certain chemicals and a family
expected to take the lives of more than 160,000history of lung cancer.
Americans this year, often within a short time of"Lung cancer is responsible for more than
diagnosis, according to the American Cancerone-third of all U.S. cancer deaths, killing more
Society. However, for the first time, patients withpeople than breast, prostate, colon, liver and
the most common type of advanced lung cancerkidney cancers combined," said Laurie Fenton,
have a targeted therapy that, withpresident of the Lung Cancer Alliance in
chemotherapy, extended overall survival beyondWashington, D.C. "The approval of Avastin is a
one year in a large, randomized clinical study.significant stride in the right direction."
AvastinĀ® (bevacizumab), a targeted therapeuticThe most common Grade 3-5 (severe) adverse
antibody (not a chemotherapy), is now approvedevents in Study E4599 seen in Avastin-treated
by the U.S. Food and Drug Administration (FDA)patients were neutropenia (low white blood cell
to be used in combination with carboplatin andcount), fatigue, hypertension (high blood pressure),
paclitaxel for the first-line treatment of patientsinfection and hemorrhage (bleeding).
with unresectable, locally advanced, recurrent orIn Study E4599, the rate of pulmonary
metastatic nonsquamous, non-small cell lunghemorrhage requiring medical intervention (bleeding
cancer (NSCLC). NSCLC is the most commonfrom the lungs for which medical treatment was
type of lung cancer.needed) for the paclitaxel and carboplatin plus
In a pivotal clinical study (Study E4599), addingAvastin arm was 2.3 percent (10 of 427),
Avastin to carboplatin and paclitaxel improvedcompared to 0.5 percent for the paclitaxel and
survival by 25 percent compared tocarboplatin alone arm (2 of 441). There were
chemotherapy alone, extending survival beyondseven deaths due to pulmonary hemorrhage
one year in selected first-line NSCLC patients.reported by investigators in the paclitaxel and
Avastin may cut off a tumor's blood supply bycarboplatin plus Avastin arm, as compared to one
targeting and inhibiting a protein called vascularin the paclitaxel and carboplatin alone arm.
endothelial growth factor (VEGF), which is believedThe most serious adverse events associated with
to play an important role in the growth of newAvastin across all trials were gastrointestinal
blood vessels.perforation, slow or incomplete wound healing,
"Avastin, in combination with chemotherapy, is thesevere bleeding problems at the site of a tumor,
first therapy in 10 years to improve on standardstrokes or heart problems, severe hypertension,
first-line treatment for advanced lung cancer, andnervous system and vision disturbances,
the first FDA-approved therapy ever to extendneutropenia (a reduced white blood cell count that
overall median survival for advanced lung cancermay increase the chance of infection), infection,
patients beyond one year in a large, randomizedsevere kidney malfunction and congestive heart
clinical study," said Alan Sandler, M.D., Director offailure. The most common adverse events seen
Medical Thoracic Oncology at Vanderbilt-Ingramin patients receiving Avastin with chemotherapy
Cancer Center in Nashville, Tenn., and leadacross all studies were weakness, pain, abdominal
investigator on the study. "With this survivalpain, headache, hypertension, diarrhea, nausea,
benefit, Avastin represents an important step forvomiting, loss of appetite, constipation, upper
many advanced lung cancer patients fighting thisrespiratory infection, nosebleeds, difficulty
difficult disease."breathing, mouth sores, skin irritation and
Cigarette smoking is the leading risk factor forproteinuria (a possible sign of kidney malfunction).